MANNKIND CORP (MNKD) Stock Fundamental Analysis
USA - NASDAQ:MNKD - US56400P7069 - Common Stock
5.76 USD
+0.27 (+4.92%)
5.8499 USD
+0.09 (+1.56%)
We assign a fundamental rating of 5 out of 10 to MNKD. MNKD was compared to 536 industry peers in the Biotechnology industry. MNKD has only an average score on both its financial health and profitability. MNKD is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
MNKD had positive earnings in the past year.
MNKD had a positive operating cash flow in the past year.
MNKD had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: MNKD reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of MNKD (7.85%) is better than 92.54% of its industry peers.
MNKD has a better Return On Invested Capital (21.43%) than 97.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.85% | ||
| ROE | N/A | ||
| ROIC | 21.43% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MNKD has a Profit Margin of 10.71%. This is amongst the best in the industry. MNKD outperforms 92.35% of its industry peers.
The Operating Margin of MNKD (26.40%) is better than 95.71% of its industry peers.
MNKD's Gross Margin of 77.36% is amongst the best of the industry. MNKD outperforms 83.77% of its industry peers.
In the last couple of years the Gross Margin of MNKD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.4% | ||
| PM (TTM) | 10.71% | ||
| GM | 77.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MNKD is creating value.
Compared to 1 year ago, MNKD has more shares outstanding
MNKD has more shares outstanding than it did 5 years ago.
MNKD has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -6.71, we must say that MNKD is in the distress zone and has some risk of bankruptcy.
MNKD has a worse Altman-Z score (-6.71) than 66.98% of its industry peers.
The Debt to FCF ratio of MNKD is 10.09, which is on the high side as it means it would take MNKD, 10.09 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MNKD (10.09) is better than 91.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 10.09 | ||
| Altman-Z | -6.71 |
ROIC/WACC2.28
WACC9.41%
2.3 Liquidity
MNKD has a Current Ratio of 2.50. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.50, MNKD is doing worse than 69.03% of the companies in the same industry.
MNKD has a Quick Ratio of 2.24. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.24, MNKD is not doing good in the industry: 70.15% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.5 | ||
| Quick Ratio | 2.24 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 125.00% over the past year.
Looking at the last year, MNKD shows a very strong growth in Revenue. The Revenue has grown by 21.46%.
Measured over the past years, MNKD shows a very strong growth in Revenue. The Revenue has been growing by 35.29% on average per year.
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)21.46%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%5.72%
3.2 Future
Based on estimates for the next years, MNKD will show a very strong growth in Earnings Per Share. The EPS will grow by 43.96% on average per year.
Based on estimates for the next years, MNKD will show a quite strong growth in Revenue. The Revenue will grow by 14.31% on average per year.
EPS Next Y34.78%
EPS Next 2Y25.88%
EPS Next 3Y31.55%
EPS Next 5Y43.96%
Revenue Next Year15.76%
Revenue Next 2Y18.02%
Revenue Next 3Y14.95%
Revenue Next 5Y14.31%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 64.00, MNKD can be considered very expensive at the moment.
Based on the Price/Earnings ratio, MNKD is valued cheaper than 91.42% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.86, MNKD is valued quite expensively.
With a Price/Forward Earnings ratio of 45.43, MNKD can be considered very expensive at the moment.
89.55% of the companies in the same industry are more expensive than MNKD, based on the Price/Forward Earnings ratio.
MNKD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 64 | ||
| Fwd PE | 45.43 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MNKD is valued cheaply inside the industry as 94.03% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 92.35% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 61.39 | ||
| EV/EBITDA | 19.52 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MNKD does not grow enough to justify the current Price/Earnings ratio.
MNKD's earnings are expected to grow with 31.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.84
PEG (5Y)N/A
EPS Next 2Y25.88%
EPS Next 3Y31.55%
5. Dividend
5.1 Amount
MNKD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.76
+0.27 (+4.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners55.89%
Inst Owner Change0%
Ins Owners1.51%
Ins Owner Change2.5%
Market Cap1.77B
Analysts84.62
Price Target10.78 (87.15%)
Short Float %5.55%
Short Ratio3.81
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-55.44%
Min EPS beat(2)-100%
Max EPS beat(2)-10.87%
EPS beat(4)0
Avg EPS beat(4)-40.95%
Min EPS beat(4)-100%
Max EPS beat(4)-10.87%
EPS beat(8)2
Avg EPS beat(8)-37.57%
EPS beat(12)5
Avg EPS beat(12)-17.45%
EPS beat(16)6
Avg EPS beat(16)-13.49%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-4.55%
Max Revenue beat(2)0.9%
Revenue beat(4)2
Avg Revenue beat(4)-2.76%
Min Revenue beat(4)-7.78%
Max Revenue beat(4)0.9%
Revenue beat(8)5
Avg Revenue beat(8)1.49%
Revenue beat(12)8
Avg Revenue beat(12)4.61%
Revenue beat(16)11
Avg Revenue beat(16)4.15%
PT rev (1m)14.29%
PT rev (3m)12.12%
EPS NQ rev (1m)33.32%
EPS NQ rev (3m)-36.51%
EPS NY rev (1m)-20.43%
EPS NY rev (3m)-41.81%
Revenue NQ rev (1m)3.69%
Revenue NQ rev (3m)4.73%
Revenue NY rev (1m)1.6%
Revenue NY rev (3m)2.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 64 | ||
| Fwd PE | 45.43 | ||
| P/S | 5.86 | ||
| P/FCF | 61.39 | ||
| P/OCF | 51.16 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 19.52 |
EPS(TTM)0.09
EY1.56%
EPS(NY)0.13
Fwd EY2.2%
FCF(TTM)0.09
FCFY1.63%
OCF(TTM)0.11
OCFY1.95%
SpS0.98
BVpS-0.18
TBVpS-0.2
PEG (NY)1.84
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.85% | ||
| ROE | N/A | ||
| ROCE | 26.57% | ||
| ROIC | 21.43% | ||
| ROICexc | 45.85% | ||
| ROICexgc | 48.02% | ||
| OM | 26.4% | ||
| PM (TTM) | 10.71% | ||
| GM | 77.36% | ||
| FCFM | 9.54% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score8
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 10.09 | ||
| Debt/EBITDA | 3.03 | ||
| Cap/Depr | 67.99% | ||
| Cap/Sales | 1.91% | ||
| Interest Coverage | 5.4 | ||
| Cash Conversion | 39.2% | ||
| Profit Quality | 89.07% | ||
| Current Ratio | 2.5 | ||
| Quick Ratio | 2.24 | ||
| Altman-Z | -6.71 |
F-Score8
WACC9.41%
ROIC/WACC2.28
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y34.78%
EPS Next 2Y25.88%
EPS Next 3Y31.55%
EPS Next 5Y43.96%
Revenue 1Y (TTM)21.46%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%5.72%
Revenue Next Year15.76%
Revenue Next 2Y18.02%
Revenue Next 3Y14.95%
Revenue Next 5Y14.31%
EBIT growth 1Y74.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y150.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y229.39%
OCF growth 3YN/A
OCF growth 5YN/A